Carnicer Maria J, Lasa Adriana, Buschbeck Marcus, Serrano Elena, Carricondo Maite, Brunet Salut, Aventin Anna, Sierra Jorge, Di Croce Luciano, Nomdedeu Josep F
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Ann Hematol. 2008 Oct;87(10):819-27. doi: 10.1007/s00277-008-0528-2. Epub 2008 Jun 28.
The CEBPA gene codes for a transcription factor that has a pivotal role in controlling proliferation and differentiation of myeloid progenitors. Acquired CEBPA mutations have been found in acute myeloid leukemias (AML) with a good prognosis, and most of these patients have a normal karyotype. In this paper, we report four cases that displayed the same K313dup in the CEBPA gene. All four had an AML-M1 with CD7 positivity and T-cell receptor gamma chain (TCR-gamma) rearrangement. This mutation could represent nearly 10% of all CEBPA mutations described to date. K313dup disappeared in samples from patients in complete remission. In transfected cells, the K313dup mutant had reduced protein stability with respect to the wild-type protein. K313dup seems to be selected in leukemic cells, and its frequency in other AML series could be determined using the screening method reported in this paper.
CEBPA基因编码一种转录因子,该转录因子在控制髓系祖细胞的增殖和分化中起关键作用。在预后良好的急性髓系白血病(AML)中发现了获得性CEBPA突变,并且这些患者中的大多数具有正常核型。在本文中,我们报告了4例在CEBPA基因中显示相同K313dup的病例。所有4例均为AML-M1,伴有CD7阳性和T细胞受体γ链(TCR-γ)重排。该突变可能占迄今为止描述的所有CEBPA突变的近10%。完全缓解患者样本中K313dup消失。在转染细胞中,K313dup突变体相对于野生型蛋白的蛋白质稳定性降低。K313dup似乎在白血病细胞中被选择,并且可以使用本文报道的筛选方法确定其在其他AML系列中的频率。